Slide 1: 9M 2025 Results Presentation
• 9M 2025 RESULTS PRESENTATION • November 12th, 2025
Slide 2: Executive Summary
ibdroot\projects\IBD-LN\fiberglass2019\643420_1\7. Marketing Materials\03 Analyst Presentation\Project Vicky_Analyst Presentation_ v55.pptx Executive Summary 9M 2025 key trends and figures Healthcare and Life Sciences sales +4.8% excl. FX and US dialysis vs. 9M 2024 Safety revenues +8.5% YoY excl. F
Slide 3: 9M 2025 Results At-a-Glance
ibdroot\projects\IBD-LN\fiberglass2019\643420_1\7. Marketing Materials\03 Analyst Presentation\Project Vicky_Analyst Presentation_ v55.pptx 9M 2025 Results At-a-Glance Growing profitability, despite adverse FX and weak dialysis contribution SALES Adjusted EBITDA and % Net Financial Position and Leve
Slide 4: Sales – 9M 2025 vs. 9M 2024
ibdroot\projects\IBD-LN\fiberglass2019\643420_1\7. Marketing Materials\03 Analyst Presentation\Project Vicky_Analyst Presentation_ v55.pptx Sales – 9M 2025 vs. 9M 2024 +0.2% YoY growth excl. FX, supported by M&A contribution and pricing SALES – 9M 2024 TO 9M 2025 BRIDGE €m 321.7 • +0.2% growth excl.
Slide 5: Sales – 9M 2025 Performance by Division
ibdroot\projects\IBD-LN\fiberglass2019\643420_1\7. Marketing Materials\03 Analyst Presentation\Project Vicky_Analyst Presentation_ v55.pptx Sales –9M 2025 Performance by Division Safety division leading Group’s sales growth Healthcare & Life Sciences Safety Energy & Mobility €m €m €m Excl. FX Excl.
Slide 6: Adj. EBITDA – 9M 2025 vs. 9M 2024
ibdroot\projects\IBD-LN\fiberglass2019\643420_1\7. Marketing Materials\03 Analyst Presentation\Project Vicky_Analyst Presentation_ v55.pptx Adj. EBITDA – 9M 2025 vs. 9M 2024 67bps of margin accretion, supported by pricing ADJ. EBITDA – 9M 2024 TO 9M 2025 BRIDGE €m 24.3% ADJUSTED EBITDA % 24.9% 67bps
Slide 7: Adj. Net Income – 9M 2025 vs. 9M 2024
ibdroot\projects\IBD-LN\fiberglass2019\643420_1\7. Marketing Materials\03 Analyst Presentation\Project Vicky_Analyst Presentation_ v55.pptx Adj. Net Income – 9M 2025 vs. 9M 2024 +7.2% YoY growth excl. FX impact Adj. Net Income Adj. Net Income Excl. FX Gains/Losses €m €m +7.2% 36.3 28.9 33.9 20.7 11.
Slide 8: Net Financial Position – 9M 2025 vs. 9M 2024
ibdroot\projects\IBD-LN\fiberglass2019\643420_1\7. Marketing Materials\03 Analyst Presentation\Project Vicky_Analyst Presentation_ v55.pptx Net Financial Position – 9M 2025 vs. 9M 2024 Leverage at 2.5x post Whole Blood acquisition NET FINANCIAL POSITION – FY 2024 TO 9M 2025 BRIDGE €m 2.1x LEVERAGE R
Slide 9: Current trading, 2025 guidance and expected trends
ibdroot\projects\IBD-LN\fiberglass2019\643420_1\7. Marketing Materials\03 Analyst Presentation\Project Vicky_Analyst Presentation_ v55.pptx Current trading, 2025 guidance and expected trends Updated FY 2025 guidance – FY 2026 expected trends • Production transfer from Haemonetics to GVS plant comple
Slide 10: 9M 2025 Results – Financial Statements
ibdroot\projects\IBD-LN\fiberglass2019\643420_1\7. Marketing Materials\03 Analyst Presentation\Project Vicky_Analyst Presentation_ v55.pptx 9M 2025 Results – Financial Statements 9M 2024 and 9M 2025 P&L – Statutory Adjusted View of which 9M 2024 of which 9M 2025 €m 9M 2024 % 9M 2025 % non-recurring
Slide 11: 9M 2025 Results – Financial Statements
ibdroot\projects\IBD-LN\fiberglass2019\643420_1\7. Marketing Materials\03 Analyst Presentation\Project Vicky_Analyst Presentation_ v55.pptx 9M 2025 Results – Financial Statements Reclassified Balance Sheet - FY 2024 – 9M 2025 As of As of €m 31-Dec-2024 30-Sep-2025 Net intangible fixed assets 472.9 4
Slide 12: 9M 2025 Results – Financial Statements
ibdroot\projects\IBD-LN\fiberglass2019\643420_1\7. Marketing Materials\03 Analyst Presentation\Project Vicky_Analyst Presentation_ v55.pptx 9M 2025 Results – Financial Statements Cash Flow Statement – 9M 2024 – 9M 2025 €m 9M 2024 9M 2025 Pre-tax result 21.8 12.1 Amortisation, depreciation and writed
Slide 13: Disclaimer
ibdroot\projects\IBD-LN\fiberglass2019\643420_1\7. Marketing Materials\03 Analyst Presentation\Project Vicky_Analyst Presentation_ v55.pptx Disclaimer Pursuant to art. 154-bis, paragraph 2, of the Italian Unified Financial Act of February 24, 1998, the executive in charge of preparing the corporate